Cyltezo — CareFirst (Caremark)

Initial criteria

• Authorization may be granted for adult members who have previously received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for active psoriatic arthritis.

Reauthorization criteria

• Continuation requests require chart notes or medical record documentation supporting positive clinical response.

Approval duration

12 months